BIOASIS TECHNOLOGIES INC - BIOAF STOCK NEWS

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) announces its Annual General Meeting on December 16, 2021, at 11:00 a.m. EST in New Haven, CT. Shareholders are urged to vote by proxy due to ongoing COVID-19 concerns.

Five nominees for director positions will be presented at the meeting, with additional information shared via a management circular. A conference call and webcast option will be available for participation.

Bioasis Technologies Inc. has filed its unaudited quarterly financial statements for the period ending August 31, 2021. The company is developing its proprietary xB3™ platform technology aimed at delivering therapeutics across the blood-brain barrier for treating central nervous system disorders, including brain cancers and neurodegenerative diseases.

The financial statements and management discussions can be accessed on SEDAR and the company's website.

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) has announced that Dr. Deborah Rathjen, Executive Chair, will attend upcoming industry conferences. The events include the Sachs - 21st Annual Biotech in Europe Forum on October 7-8, 2021, where she will participate in a panel on neuroinflammation. Additionally, she will present at the BIO-Europe Digital Conference from October 25-28, 2021, focusing on building partnerships in biopharma.

Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) has appointed Shadow Lake Group as its Business Development advisor to further its strategic partnerships and commercialization efforts. The collaboration aims to leverage SLG's expertise in neuroscience and oncology, enhancing Bioasis' proprietary xB3™ platform technology aimed at treating CNS disorders. Executive Chair Deborah Rathjen expressed optimism about this engagement, highlighting the potential for significant advancements in the company's scientific and business initiatives.

Bioasis Technologies has announced the issuance of Japanese Patent No. 2019-189551 for its xB³-IDS fusion proteins, which enhances the delivery of biologics across the blood-brain barrier. This patent covers compositions related to lysosomal storage diseases, including Hunter Syndrome. The patent is a significant milestone for Bioasis, bolstering its intellectual property in a crucial market. The company previously received a similar patent in Australia, further strengthening its position in the biopharmaceutical sector.

Bioasis Technologies Inc. (BIOAF) announced the filing of its unaudited quarterly financial statements for the period ended May 31, 2021. The company is developing its proprietary xB³™ platform to deliver therapeutics across the blood-brain barrier (BBB), targeting CNS disorders like brain cancers and neurodegenerative diseases. The financial reports are accessible on SEDAR and Bioasis' website. The company faces challenges typical of preclinical biotech firms, including dependency on additional funding and regulatory approvals.

Bioasis Technologies Inc (TSXV:BTI; OTCQB:BIOAF) announced the grant of stock options for 1,367,606 common shares at $0.38 each, effective June 30, 2020, to directors, officers, and an investor relations consultant. These options, expiring in five years, are part of annual remuneration aimed at enhancing R&D investment. Additionally, Dr. Jeffrey Sprouse was appointed as Preclinical Program Manager, bringing over 20 years of drug discovery experience. His expertise is expected to contribute significantly to advancing Bioasis's drug delivery technology for CNS disorders.

Bioasis Technologies (TSXV:BTI; OTCQB:BIOAF) announced positive results from a preclinical study of its xB³™ platform, showing efficacy in delivering an interleukin-1 receptor inhibitor across the blood-brain barrier in a rodent model of multiple sclerosis. Treatment with xB³™-IL-1RA led to delayed onset and reduced clinical symptoms compared to control groups. Dr. Deborah Rathjen emphasized the technology's potential to treat neuroinflammatory disorders. These findings support the ongoing development of xB³™ as a solution for CNS conditions with high unmet medical needs.

Bioasis Technologies has appointed Dave Jenkins as the new Chief Financial Officer, effective July 1, 2021. Jenkins, with over 35 years of financial management experience, aims to drive the company's strategic and financial plans as it advances its proprietary xB3™ platform for treating CNS disorders. His background includes significant roles in technology and life sciences firms, and he will support Bioasis in achieving critical developmental milestones. The Board expressed gratitude to outgoing CFO Christine Antalik for her contributions. Bioasis focuses on delivering therapeutics across the blood-brain barrier.